← Markets

Axsome Therapeutics, Inc.

AXSM · NASDAQ

Market closed$230.00$-7.04 (-2.97%)After hours $232.10 · +0.91%

Key statistics

Previous close$237.04
Open$233.62
Day high$237.36
Day low$228.12
52-week high$260.19
52-week low$96.09
Market cap11.84B
Volume828.58K
Average volume933.10K
P/E ratio-60.05
Forward P/E—
EPS-3.83
Dividend yield0.00%

Market context

Why it moved

AXSM shares declined after the company's latest quarterly earnings report revealed a significant miss on the bottom line, with EPS coming in well below analyst estimates despite strong revenue growth, raising investor concerns about profitability.

MarketbeatInstagramStockinvestInstagramStockanalysis

What is happening

Recent company-specific developments and publisher coverage.

July 16, 2026Axsome Therapeutics closed essentially flat as investors digested a key regulatory milestone: the FDA accepted the company's New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, with a PDUFA action date set for May 1, 2027, and no advisory committee meeting currently planned. The NDA acceptance expands Axsome's CNS pipeline beyond its approved Auvelity and Sunosi franchises, adding a potential catalyst in 2027. With Q2 earnings scheduled for August 10, analysts maintain a Moderate Buy consensus and an average price target of $259.05, well above current levels, following a new institutional investment from Hillsdale Investment Management and recent price target raises from Royal Bank of Canada ($304) and Deutsche Bank ($280).

-0.2063

July 16, 2026Axsome Therapeutics edged higher after the FDA accepted its New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027 — and notably indicating no advisory committee meeting is planned, a sign often viewed favorably by investors. The NDA acceptance broadens Axsome's regulatory pipeline following its earlier Alzheimer's agitation work with AXS-05, reinforcing the CNS-focused company's multi-asset growth story ahead of its Q2 earnings report on August 10.

0.9649

July 15, 2026Axsome Therapeutics gained over 3% as investors responded positively to the company's announcement of its Q2 2026 earnings date (August 10), alongside continued institutional accumulation — including a new position from Hillsdale Investment Management — and a broadly favorable macro backdrop after June CPI came in softer than expected at 3.5%, lifting growth-oriented biotech names. Analyst consensus remains firmly bullish with a Moderate Buy rating and an average price target of $259.05, with Auvelity's strong prescription growth and a potential Alzheimer's agitation label expansion keeping sentiment constructive heading into earnings.

3.0576

July 14, 2026Axsome Therapeutics fell over 2% as broad market risk-off sentiment weighed on biotech names, with renewed U.S.-Iran military hostilities sending oil prices surging and pressuring equities broadly. The decline follows a rough stretch for AXSM: shares dropped ~5.7% last Thursday amid profit-taking and lingering concern over CEO Herriot Tabuteau's sale of ~49,670 shares in June, with no new negative company-specific catalyst identified. Despite the near-term pressure, analyst sentiment remains firmly bullish—Royal Bank of Canada boosted its price target to $304 on July 7, and the consensus median target sits around $259.50, well above current levels. The broader biotech sector, which Goldman Sachs recently highlighted as having "extremely strong fundamentals" driven by M&A and innovation tailwinds, also declined on Monday as the healthcare ETF (XLV) slipped alongside the broader S&P 500 selloff.

-2.361

July 11, 2026Axsome Therapeutics tumbled sharply, significantly underperforming both the broader healthcare sector (XLV essentially flat) and the S&P 500 (up ~0.4%), even as biotech broadly remains a market leader. The sell-off appears tied to a combination of headwinds: notable insider selling (CFO sold ~$7.9M in shares in June, with insiders offloading over $38.6M in the past 90 days), a Q1 EPS miss of $0.41 below consensus, and growing concern that Medicaid cuts under the One Big Beautiful Bill Act could dampen revenue projections for CNS-focused biotechs. Despite a mostly bullish analyst consensus ("Moderate Buy," avg. target ~$259) and the recent initiation of the FOCUS-2 Phase 3 trial of solriamfetol in pediatric ADHD, investor sentiment soured on the day.

-6.0856

July 10, 2026Axsome Therapeutics closed modestly higher, outperforming the broader healthcare sector as investors continue to warm to the CNS-focused biotech's growth story. The gain comes amid a favorable backdrop for biotech, with Jim Cramer calling it 'the hottest group in the market' and predicting a wave of M&A activity under the new FDA leadership — a narrative that could benefit Axsome given its late-stage pipeline. Adding to momentum, Axsome dosed the first patient in its FOCUS-2 Phase 3 trial of solriamfetol in pediatric ADHD just this week, expanding its pipeline optionality. Analyst sentiment remains constructive with a consensus 'Moderate Buy' and average price target of ~$259, though Q1 earnings showed strong 57.4% revenue growth to $191.2M alongside a notable EPS miss, and insider selling over the past 90 days has been elevated.

1.3764

July 9, 2026Axsome Therapeutics closed modestly lower as a broader risk-off session weighed on equities after President Trump declared the U.S.-Iran ceasefire 'over,' sending oil prices surging and triggering a market-wide selloff. The decline came despite a positive pipeline catalyst — Axsome dosed the first patient in its FOCUS-2 Phase 3 trial of solriamfetol in children with ADHD, complementing the recently initiated FOCUS-3 adolescent trial. Analyst sentiment remains broadly bullish, with a consensus 'Moderate Buy' rating and average price target of ~$259, and shares rebounded in after-hours trading, recovering roughly half the day's loss.

-1.6776

July 8, 2026Axsome Therapeutics gained nearly 3% on elevated volume after dosing the first patient in FOCUS-2, its Phase 3 trial of solriamfetol in children aged 6–12 with ADHD — expanding its pipeline beyond the recently approved adult indication. RBC Capital also raised its price target to $304 (from $302), maintaining an Outperform rating. The clinical catalyst lands against a favorable sector backdrop, with biotech emerging as the market's hottest group amid rising M&A optimism and the XLV healthcare ETF near 52-week highs.

2.9514

Webull · July 16, 2026Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?TradingView · July 15, 2026Axsome Therapeutics NDA for AXS-12 accepted by FDA; PDUFA date May 1, 2027GlobeNewswire · July 15, 2026Axsome Therapeutics Announces FDA Acceptance of New DrugSimply Wall Street · July 15, 2026Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy CataplexySimply Wall Street · June 16, 2026Axsome Therapeutics (AXSM) Presented New Phase 3 Sleep Disorder Data That Investors Will WatchInvesting.com · June 4, 2026H.C. Wainwright reiterates Axsome stock rating on patent settlementStocktwits · February 23, 2026Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For StockStock Titan · January 27, 2026Axsome investors get Q4 and full-year 2025 results ahead of Feb. 23 call
Mt Newswire · July 15, 2026Axsome Therapeutics Wins US FDA Review for Narcolepsy Drug Application
Benzinga · July 15, 2026Axsome Therapeutics Says FDA Accepts NDA For AXS-12 For Treatment Of Cataplexy In Narcolepsy; PDUFA Target Action Date Set May 1, 2027
Benzinga · July 7, 2026RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $304
Mt Newswire · July 7, 2026RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating
Mt Newswire · July 7, 2026Axsome Therapeutics Doses First Patient in Trial of Potential ADHD Drug
Benzinga · July 7, 2026Axsome Therapeutics Doses First Patient In FOCUS-2 Phase 3 Trial Of Solriamfetol For Children With Attention Deficit Hyperactivity Disorder
Mt Newswire · June 26, 2026Axsome Therapeutics Says First Patient Dosed in Phase 3 Solriamfetol ADHD Study
Benzinga · June 26, 2026Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder

Peers

S&P 500SPX · $7,457.69-1.01%Jazz Pharmaceuticals plcJAZZ · $247.53+2.21%Corcept Therapeutics IncorporatedCORT · $90.52+0.89%Prestige Consumer Healthcare Inc.PBH · $49.92-1.34%Perrigo Company plcPRGO · $10.72-3.94%ACADIA Pharmaceuticals Inc.ACAD · $25.60-0.12%Madrigal Pharmaceuticals, Inc.MDGL · $553.48+1.46%Cytokinetics, IncorporatedCYTK · $80.18-0.22%BridgeBio Pharma, Inc.BBIO · $81.38+1.34%Ionis Pharmaceuticals, Inc.IONS · $54.39-0.48%Nuvalent, Inc.NUVL · $123.960.00%BioMarin Pharmaceutical Inc.BMRN · $59.59-0.68%